ImmuPharma plc (AIM:IMM)

Revenue by Segment

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development and Commercialisation of Pharmaceutical Products					118.35K	126.67K	77.93K	81.28K	150.46K
Development and Commercialisation of Pharmaceutical Products Growth					-6.57%	62.55%	-4.13%	-45.98%	-8.69%
Total					118.35K	126.67K	77.93K	81.28K	150.46K
Total Growth					-6.57%	62.55%	-4.13%	-45.98%	-8.69%

Revenue by Geography

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
France					68.11K	105.14K	54.75K	77.34K	150.46K
France Growth					-35.22%	92.04%	-29.21%	-48.60%	-8.69%
Switzerland					50.24K	21.53K	23.18K	3.94K	-
Switzerland Growth					133.42%	-7.12%	487.78%	-	-
Total					118.35K	126.67K	77.93K	81.28K	150.46K
Total Growth					-6.57%	62.55%	-4.13%	-45.98%	-8.69%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 4, 2026

Data Sources Report a data error